Search Results - gary+posner

4 Results

Sort By:

Artemisinin dimers as potent anti-cytomegalovirus (CMV) agents

UNMET NEED: Infection with cytomegalovirus (CMV) is common in humans and is usually asymptomatic; yet, in immunocompromised hosts, such as transplant recipients and patients with AIDS, CMV infection is associated with significant morbidity and mortality. Cytomegalovirus infection also is the most common congenitally-acquired infection and the leading...

Published: 5/2/2024 | Inventor(s): Gary Posner, Ravit Boger

Keywords(s): Antagonists/Inhibitors, Cytomegalovirus, Disease Indication, Infectious Diseases, Novel, Predicted Novelty, Single, Small Molecules, Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Viral Infections

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases > Cytomegalovirus, Clinical and Disease Specializations > Infectious Diseases > Viral Infections, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities

Antimalarial Thioacetal Trioxanes in the Artemisinin Family

C11864: Novel Artemisinin Analog Antimalarial DrugsNovelty: The inventors have created several semisynthetic analogs of artemisinin with antimalarial properties.Value Proposition: In 2010, malaria affected over 216 million people, and while treatments for malaria exist, malaria parasites have grown resistant to several of the commonly used, quinoline-based...

Published: 5/2/2024 | Inventor(s): Alexander Jacobine, Rachel Slack, Jennifer Mazzone, Gary Posner

Keywords(s): Antagonists/Inhibitors, Disease Indication, Infectious Diseases, Malaria, Novel, Parasitic Infections, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases > Malaria, Clinical and Disease Specializations > Infectious Diseases > Parasitic Infections, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities

Monomeric Trioxane Amide Sulfur Compounds

C11486: Oral Single Dose Therapeutic for MalariaNovelty: The combination of a novel oral drug with Mefloquine administered as a single oral dose demonstrates anti-malarial activity.Value Proposition: Malaria is responsible for a million deaths each year and some treatments are not very effective, as the malarial parasite has developed resistance to...

Published: 5/2/2024 | Inventor(s): Rachel Slack, Gary Posner

Use of Novel Derivatives of Artemisinin To Inhibit Toxoplasma Gondii

C05086: Use of Novel Derivatives of Artemisinin To Inhibit Toxoplasma Gondii Technical Details: Toxoplasmosis, caused by the protozoan Toxoplasma gondii, is a medically important infection that is distributed worldwide. Current treatments for the prevention and treatment of toxoplasmosis are of limited efficacy and have undesirable side-effects. According...

Published: 5/2/2024 | Inventor(s): John D'angelo, Gary Posner, Robert Yolken, Lorraine Brando

Keywords(s): Antagonists/Inhibitors, Disease Indication, Infectious Diseases, Novel, Parasitic Infections, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Toxoplasmosis

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases > Parasitic Infections, Clinical and Disease Specializations > Infectious Diseases > Toxoplasmosis, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities